Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 plus chemotherapy in EGFR-mutant non-squamous NSCLC
NCT05756972Phase 2Active, not recruiting
- Sponsor
- Biotheus
- Start
- Jun 2023
- Primary completion
- Sep 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pumitamig in non-small cell lung cancer (NSCLC), sponsored by Biotheus. Started Jun 2023; status: active, not recruiting.
02
Drugs
pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05756972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05756972.